{
    "nct_id": "NCT03599713",
    "official_title": "A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)",
    "inclusion_criteria": "* Signed informed consent.\n* Diagnosis of MCC with distant metastatic disease or recurrent, advanced locoregional disease not amenable to surgery or radiation\n* Eastern Cooperative Oncology Group performance status of 0 to 1.\n* Measurable disease according to RECIST v1.1.\n* Availability of tumor tissue (fresh or archival) for central pathology review.\n* Willingness to avoid pregnancy or fathering children based on protocol-defined criteria.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior systemic therapy for MCC, including chemotherapy and prior PD-1 or PD-L1-directed therapy.\n* Treatment with anticancer drugs or participation in another interventional clinical study within 21 days before the first administration of study drug.\n* Has not recovered to â‰¤ Grade 1 or baseline from toxic effects of prior therapy (with the exceptions for anemia not requiring transfusion support and any grade of alopecia) and/or complications from prior surgical intervention within 7 days before starting study treatment.\n* Radiation therapy administered within 2 weeks of first dose of study treatment or radiation therapy to the thoracic region that is > 30 Gy within 6 months of the first dose of study treatment.\n* Known central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* History of second malignancy within 3 years (with exceptions).\n* Laboratory values outside the protocol-defined range at screening.\n* Clinically significant pulmonary, cardiac, gastrointestinal or autoimmune disorders.\n* Active bacterial, fungal, or viral infections, including hepatitis A, B, and C.\n* Receipt of a live vaccine within 28 days of planned start of study therapy.\n* Current use of protocol-defined prohibited medication.\n* Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).\n* Inability or unlikely, in the opinion of the investigator, to comply with the Protocol requirements.\n* Participant who is pregnant or breastfeeding.",
    "miscellaneous_criteria": ""
}